Sanofi Rheumatoid Arthritis Drug Cuts Pain, Damage in Study

Sanofi and Regeneron Pharmaceuticals Inc.’s experimental rheumatoid arthritis drug eased symptoms and damage caused by the disease in a clinical trial, advancing its prospects to compete in a market led by Roche Holding AG.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.